Vanguard Personalized Indexing Management LLC Acquires New Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Vanguard Personalized Indexing Management LLC bought a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 12,659 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Other hedge funds have also made changes to their positions in the company. Arizona State Retirement System increased its holdings in Revance Therapeutics by 27.6% in the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,996 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Revance Therapeutics by 67.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 6,826 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Revance Therapeutics by 9.8% in the 1st quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 8,668 shares during the last quarter. Certuity LLC purchased a new stake in shares of Revance Therapeutics in the 2nd quarter valued at about $26,000. Finally, EntryPoint Capital LLC grew its position in shares of Revance Therapeutics by 109.4% during the first quarter. EntryPoint Capital LLC now owns 19,906 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,400 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $5.20 on Wednesday. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $11.49. The business’s fifty day moving average is $5.51 and its two-hundred day moving average is $4.24.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. The firm’s quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.80) earnings per share. As a group, equities analysts expect that Revance Therapeutics, Inc. will post -1.53 EPS for the current year.

Wall Street Analyst Weigh In

RVNC has been the topic of several recent research reports. Needham & Company LLC cut shares of Revance Therapeutics from a “moderate buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. StockNews.com initiated coverage on shares of Revance Therapeutics in a report on Tuesday. They issued a “hold” rating for the company. Finally, Barclays restated an “equal weight” rating and set a $7.00 target price (down from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Ten research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Revance Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.50.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.